Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Recent advances in, and challenges of, designing OMA1 drug screens

Pharmacological Research(2022)10.1016/j.phrs.2022.106063Source: DataRank Database

Recent advances in, and challenges of, designing OMA1 drug screens is a research paper published in Pharmacological Research (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

refsnp doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.63)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Marcel V. Alavi ORCID

Live enrichment

PubMed:34999225 PMC:PMC8923697 OpenAlex:https://openalex.org/W4206619407

NIA

Grant: R43AG063642

National Institutes of Health

Grant: 1R43AG063642-01

Discovery and validation of OMA1 inhibitors

National Institutes of Health

FWCI

0.63

Citation Percentile

0.6%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8923697

BRONZEhttps://www.sciencedirect.com/science/article/am/pii/S1043661822000081

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8923697

publisherhttps://api.elsevier.com/content/article/PII:S1043661822000081?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1043661822000081?httpAccept=text/plain

Fields of Study

Mitochondrial Function and PathologyATP Synthase and ATPases ResearchAutophagy in Disease and TherapyMedicineChemistry0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsDrug DesignHigh-Throughput Screening AssaysHumansMetalloendopeptidases

MeSH Terms

AnimalsHumansMetalloendopeptidasesDrug DesignHigh-Throughput Screening Assays

Keywords

ProteasesNeurodegenerationContext (archaeology)MitochondrionBiologyProteaseNeuroscienceBioinformaticsDiseaseMedicineCell biologyEnzymeBiochemistryPathologyMitochondriaCancerProtease inhibitorsdrug discoveryMg132 (Pubchem Cid: 462382)Tamoxifen (Pubchem Cid: 2733526)Sb216763 (Pubchem Cid: 176158)Sorafenib (Pubchem Cid: 216239)Membrane ProteasesValinomycin (Pubchem Cid: 3000706)Cccp (Pubchem Cid: 2603)Azd1080 (Pubchem Cid: 135564570)Ceritinib (Pubchem Cid: 57379345)Drug DesignAnimalsHumansMetalloendopeptidasesHigh-Throughput Screening Assays

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Recent advances in, and challenges of, designing OMA1 drug screens

FAIR Checklist

Authors (1)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)